gastro oesophageal junction
Astellas’ application to EMA validated for treatment of muscle-invasive bladder cancer
Bladder cancer affects over 224,000 people annually in Europe, with over 30% of cases being muscle-invasive bladder cancer
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers
In 2022, nearly one million new patients were diagnosed with gastric cancer
AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer
Gastric cancer is the fifth leading cause of cancer-related deaths globally
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer
Almost one million cases of the disease are diagnosed globally every year
BeiGene’s Tevimbra combination granted FDA approval to treat gastric cancer
Approximately 27,000 cases of the disease were diagnosed in the US in 2024
BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use
Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth
BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer
Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth
Astellas’ Vyloy approved by FDA as first-line gastric cancer combination treatment
Approximately 26,890 new cases of gastric cancer will be diagnosed in the US this year
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
About 614,000 people are diagnosed with bladder cancer globally every year